Osteoporosis of the Femur Treatment Guidelines
Diagnostic Criteria
- Osteoporosis is diagnosed when bone mineral density (BMD) at the femoral neck, total hip, or lumbar spine is ≥2.5 standard deviations below the mean BMD value for a young adult (T-score ≤ -2.5) 3
- Low bone mass (osteopenia) is defined as a BMD value between 1 and 2.5 standard deviations below the mean BMD value for a young adult (T-score between -1 and -2.5) 3
Treatment Algorithm
- The American College of Physicians recommends bisphosphonates as the first-line pharmacologic treatment for osteoporosis of the femur due to their proven efficacy in reducing fracture risk with a favorable benefit-risk profile (strong recommendation; high-certainty evidence) 1, 2, 4
- Bisphosphonates reduce the risk of vertebral, hip, and non-vertebral fractures 1
- The American College of Physicians suggests considering stopping bisphosphonates after 5 years unless a strong indication for continuation exists 5
- Denosumab (RANK ligand inhibitor) is recommended for patients with contraindications to bisphosphonates (conditional recommendation; moderate-certainty evidence) 1, 2
- Romosozumab (sclerostin inhibitor) or Teriparatide (recombinant PTH) may be considered for very high-risk patients (conditional recommendation; low-certainty evidence) 1, 2
Non-Pharmacologic Interventions
- Calcium and vitamin D supplementation are recommended, with calcium intake of 1,000-1,200 mg daily and vitamin D intake of 800-1,000 IU daily 6, 7
- Exercise, including balance training, flexibility/stretching exercises, endurance exercise, and resistance/progressive strengthening exercises, is recommended at least 3 days per week for 30 minutes 6, 7
- Lifestyle modifications, such as smoking cessation, limiting alcohol consumption, and fall prevention counseling, are recommended 6, 1
Monitoring and Follow-up
- BMD testing is recommended every 2 years for patients at high risk 6
- More frequent monitoring may be necessary based on individual risk factors 6
Potential Adverse Effects
- Bisphosphonates may cause osteonecrosis of the jaw and atypical femoral fractures, and a drug holiday may be considered after 5 years of treatment 1, 5
Special Considerations
- Patients with cancer-induced bone loss should be monitored closely 6
- Patients initially treated with anabolic agents should transition to antiresorptive therapy to maintain bone density gains 5
- Generic medications should be prescribed when possible to improve adherence and reduce costs 1